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Targeting Channels and Transporters
in Protozoan Parasite Infections
Anna Meier †, Holger Erler † and Eric Beitz*
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Infectious diseases caused by pathogenic protozoa are among the most significant
causes of death in humans. Therapeutic options are scarce and massively challenged
by the emergence of resistant parasite strains. Many of the current anti-parasite drugs
target soluble enzymes, generate unspecific oxidative stress, or act by an unresolved
mechanism within the parasite. In recent years, collections of drug-like compounds
derived from large-scale phenotypic screenings, such as the malaria or pathogen box,
have been made available to researchers free of charge boosting the identification of
novel promising targets. Remarkably, several of the compound hits have been found
to inhibit membrane proteins at the periphery of the parasites, i.e., channels and
transporters for ions and metabolites. In this review, we will focus on the progress
made on targeting channels and transporters at different levels and the potential for use
against infections with apicomplexan parasites mainly Plasmodium spp. (malaria) and
Toxoplasma gondii (toxoplasmosis), with kinetoplastids Trypanosoma brucei (sleeping
sickness), Trypanosoma cruzi (Chagas disease), and Leishmania ssp. (leishmaniasis),
and the amoeba Entamoeba histolytica (amoebiasis).
Keywords: drug target, transport, infection, resistance, parasite, malaria, protozoa
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Apicomplexa
Withmore than 200million new infections per year, malaria-causing Plasmodium spp. are the most
prominent parasites. The death toll of malaria is still >400,000 per year. About 90% of the cases
occur in the WHO African Region and are caused almost exclusively by the species Plasmodium
falciparum. In the subtropical zones outside of Africa, Plasmodium vivax is responsible for up to
64% of the cases. Ongoing efforts to eradicate malaria are hampered by the lack of effective antisera
and the spreading of resistant strains against antimalarial treatment (WHO, 2017b). Hence, current
research aims at identifying suitable epitopes for future immunization programs, and discovery of
new drug targets to establish novel modes of antimalarial drug action.
The current first-line treatment of uncomplicated P. falciparum malaria is an oral artemisinin-
based combination therapy (WHO, 2015). The mechanisms of how artemisinin and its derivatives,
such as artesunate and artemether, attain antimalarial activity are thought to reside in generating
oxidative stress by liberating reactive oxygen species from an internal peroxo-moiety, and in
affecting a calcium ATPase (SERCA or PfATP6) of the sarcoplasmic-endoplasmic reticulum
(Moore et al., 2011). The half-life of the fast-acting artemisinins is very short, typically around
1 h. To maintain this highly efficient therapeutic option in view of an increasing number of mutant
parasite strains with varying degrees of resistance to the artemisinins (Jambou et al., 2005), these
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compounds are combined with drugs that exhibit longer half-
lives (WHO, 2001; Kavishe et al., 2017). Patients infected
with P. vivax, Plasmodium ovale, Plasmodium malariae, or
Plasmodium knowlesi are equally treated with an artemisinin
combination therapy or with chloroquine depending on
the sensitivity of the infecting strain. For a number of
decades, chloroquine was used for monotherapy until massive
resistance occurred. Chloroquine accumulates in the parasite’s
digestive vacuole and interferes with heme-detoxification during
hydrolysis of hemoglobin from the host (Slater, 1993; Thomé
et al., 2013; WHO, 2015). For preventing relapse from dormant
liver stages after infections with P. vivax or P. ovale, the use of
primaquine is recommended (Fernando et al., 2011; Mikolajczak
et al., 2015; Lalève et al., 2016). Complicated infections require
rapid administration via intravenous or intramuscular injections
of artesunate for at least 24 h followed by artemisinin-based
combination therapy (Abiodun et al., 2013; WHO, 2015).
A malaria-related, tick-borne disease, babesiosis, normally
occurs in livestock and domestic animals, and only occasionally
emerges in humans. Most cases of human babesiosis are caused
by Babesia microti. First-line treatment is a combination of
the ubiquinone analog atovaquone and the antibiotic macrolide
azithromycin (Krause et al., 2000).
Another apicomplexan parasite, Toxoplasma gondii, causes
the food-borne disease toxoplasmosis. It is estimated that
30–50% of the world’s population are infected with this
parasite. It persists, often life-long, in the host in a dormant,
cystic bradyzoite form. Although the infection usually occurs
asymptomatic, it can evolve to a life-threating illness in immune-
compromised patients. Infections of pregnant women can be
transmitted to the fetus giving rise to spontaneous abortion
or stillbirth (Flegr et al., 2014). Toxoplasmosis is treated with
the dihydrofolate reductase inhibitor pyrimethamine or the
antibiotic sulfadiazine. Second-line drugs are azithromycin,
clarithromycin, atovaquone, dapsone, and cotrimoxazole. Due to
side effects and ineffectiveness against the dormant bradyzoite
form novel therapeutics are urgently needed (Petersen and
Schmidt, 2003).
Kinetoplastids
Parasites of the phylum euglenozoa, i.e., the kinetoplastids,
are the causative agents of various infections that are classified
as neglected tropical diseases. Overall, it is estimated that one
billion people in tropical and subtropical countries are affected.
Infections with Leishmania spp. lead to cutaneous (Leishmania
major, Leishmania tropica) mucocutaneous (Leishmania
braziliensis), or visceral leishmaniasis (Leishmania donovani,
Leishmania infantum), which is spread by sandflies. About
250,000 new cases are registered per year in 87 countries
(WHO, 2017a). For treatment, sodium stibogluconate,
amphotericin B, miltefosine, paromomycin, and pentamidine
are used; yet, the therapy needs major improvement as it
is characterized by high levels of toxicity for the patient.
Further, resistance against the drugs, in particular to the
pentavalent antimonial stibogluconate, strongly limits their
usability (Loiseau and Bories, 2006; Ponte-Sucre et al.,
2017).
Parasites of a related kinetoplastid species, Trypanosoma,
cause life-threatening infections, i.e., human African
trypanosomiasis or sleeping sickness (Trypanosoma brucei)
and Chagas disease (Trypanosoma cruzi). Human African
trypanosomiasis is spread by the tsetse fly in tropical Africa.
Approximately 3,000 cases were reported in 2016 (WHO, 2016).
In the first hemolytic stage, T. brucei replicates extracellularly
in the host blood causing fever and joint pain among other
symptoms. In the second, severe neurological stage of the
disease, the parasite reaches the central nervous system. Patients
suffer from disruption of the sleep-wake cycle and irreparable
neurological damage. Parasites in the peripheral blood stream
can be attacked by the drugs suramin and pentamidine. For the
central nervous system form, only the mercurial melarsoprol
and eflornithine are available (Brun et al., 2010). As in the case
of leishmaniasis, modern, i.e., less toxic and more effective drugs
are needed. T. cruzi-derived Chagas disease is prevalent in Latin-
America claiming 14.000 deaths per year. An estimated 6 million
people are infected by T. cruzi spread by the bug Triatoma
infestans (also kissing bug or winchuka). As a treatment, the
chemical radical-producing drug benznidazole and nifurtimox
are available. With only two compounds at hand, limited success
rates and severe side-effects, new drugs are required against this
parasite (Castro et al., 2006).
Amoebae
The free-living amoebozoan parasite Entamoeba histolytica
causes amoebiasis. With an estimated death toll of 40,000–
100,000 per year, it ranges second behind Plasmodium infections
(Stanley, 2003). The disease is most prevalent in but not restricted
to the tropics when sanitation is poor. Although the majority of
infections progress asymptomatically, a life-threatening amoebic
colitis can manifest. E. histolytica forms hardy, infectious
cysts that are ingested by the host via contaminated food
or water. After reaching the colon, the cysts transform into
trophozoites that are capable of invading the intestinal mucosa.
When breaching the mucosa, trophozoites can disseminate,
among others, to the liver and the central nervous system
causing serious complications, i.e., amoebic abscesses (Shirley
and Moonah, 2016). First line treatment is a combination of the
antibiotics metronidazole and paromomycin. Alternative, second
line treatments for metronidazole are other nitroimidazoles,
e.g., tinidazole or ornidazole, and the broad-spectrum anti-
parasitic nitazoxanide. Paromomycin can be substituted by
diiodohydroxyquinoline and diloxanide, both drugs act by a so-
far unresolved mechanism and may not be effective against all
strains (McAuley and Juranek, 1992).
The severity of infections by protozoan parasites, the limited
arsenal of drugs, often with hardly tolerable side effects, and
the increasing resistance problem call for novel approaches.
The scope of this review is, thus, to discuss the potential of
channel and transport proteins as novel targets for anti-parasite
chemotherapy in terms of druggability, selectivity, and proneness
to resistance. There is considerably more data available from
the malaria research field compared to the more neglected
parasite-caused diseases. A major criterion for inclusion of a
channel or transporter into this review was existing proof of
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principle involving first small-molecule inhibitors that exhibit
anti-parasitic potency.
TARGETING TRANSPORT PROCESSES OF
PARASITES AT DIFFERENT LEVELS
Transmembrane transporters and channels are usually classified
based on their biophysical and biochemical properties, such as
mechanism of transport and substrate selectivity. We decided
to provide a pharmacological and pharmaceutical view on the
topic and structured this manuscript based on the location of
the transporter of interest and, accordingly, the site of action of
a respective drug (Figure 1). We will approach the parasite from
the outside, first hitting the host cell in the case of intracellular
parasites. i. Indirect targeting. If it is possible to address infected
host cells selectively by targeting transport proteins of the host
cell plasma membrane this would leave the parasite little options
for defending itself against the attack. Malaria parasites for
instance are known to modify the functionality of red blood
cell proteins and to integrate plasmodial membrane proteins
into the erythrocyte membrane. ii. Peripheral targeting. Target
proteins residing in a parasite’s plasmamembrane possibly can be
inhibited from the outside. In this case and in indirect targeting,
resistance mechanisms would be limited to changing the drug
binding site of the target protein. iii. Internal targeting. For
targeting transporters within a parasite, i.e., at organelles such
as the digestive vacuole or mitochondria, respective drugs would
need to enter the parasite’s cytosol. In this case, the parasite
has additional means to generate resistance, either by preventing
uptake of the compound, by altering it chemically, or by pumping
it out via efflux transporters. Hence, we will also address iv.
Targeting drug efflux transporters.
Indirect Targeting—Channels and
Transporters of the Infected Host Cell
Membrane
It was recognized early on in malaria research that the transport
of ions, amino acids, and other nutrients across the plasma
membrane of infected red blood cells increases compared to
uninfected cells. This way, the parasite actively adapts the ionic
environment inside the erythrocyte to its needs and ensures
access to nutrients from the host blood. Over the years, it has
become evident that such new permeability pathways (NPP)
are not only due to infection-dependent alteration of the host
membrane proteins but also to export of Plasmodium-derived
proteins and integration into the host cell membrane (Overman,
1947; Ginsburg et al., 1985; Desai et al., 2000; Huber et al., 2002).
Proteins at the erythrocyte plasma membrane pose attractive
targeting sites as the respective inhibitor compounds would not
be in direct contact with the parasite. Interference by the parasite
with drug action would be restricted to alteration of the protein
resulting from gene mutations, whereas other means, such as
expedited drug export or metabolism would not be applicable.
It remains to be shown, however, whether this indirect approach
can reliably kill parasites (Cohn et al., 2003). The efficiency
of compounds that indirectly target parasites is summarized in
Table 1.
Plasmodial Surface Anion Channel
One extensively studied type of conductivity of the red blood cell
membrane that is brought about upon infection is derived from
the plasmodial surface anion channel (PSAC; Figure 1). Despite
a still elusive protein identity, permeability for various substrates,
such as sugars, amino acids, nucleosides, and inorganic anions
and cations, has been attributed to this voltage-dependent
channel (Ginsburg et al., 1985; Kirk and Horner, 1995; Upston
and Gero, 1995; Saliba et al., 1998; Hill et al., 2007). PSAC
seems to transport the mentioned substrates via two different
routes within the protein or protein complex. One path is said
to be used primarily for alanine and sorbitol uptake and can be
blocked by furosemide, whereas the other one conducts mainly
proline and the unnatural substrate phenyltrimethylammonium
(PhTMA). The latter path is sensitive to so-called PSAC residual
transport inhibitors, abbreviated as PRT (Alkhalil et al., 2004;
Pain et al., 2016). Based on this finding, full blockade of PSAC
may require a combination of a PRT inhibitor plus a furosemide
derivative. For example, PRT1-20 alone (Table 1) yielded an
IC50 on P. falciparum growth of 5µM; in combination with
furosemide it was 10 times lower (Pain et al., 2016). Toward
identification of the PSAC protein or regulators thereof, the
finding could become helpful that certain parasite strains are
susceptible to one particular group of PSAC inhibitors. This
pointed to two genes, CLAG3.1 and CLAG3.2 (cytoadherence
linked asexual protein) of which only one appears to be active
at a time. Mutations in the genes led to modified PSAC activity.
Further, epigenetic regulation of the CLAG3 genes was suggested
to modulate PSAC (Sharma et al., 2013; Nguitragool et al., 2014).
To illustrate this, ISPA-28 (Table 1), an isolate-specific PSAC
antagonist, exhibited an IC50 of 56 nM against the P. falciparum
Dd2 strain and 43µM against the HB3 strain, i.e., a value higher
by three orders of magnitude. When the CLAG3 gene of the
Dd2 strain was transferred to the HB3 strain, it showed the
same nanomolar susceptibility (Nguitragool et al., 2011, 2014).
Clearly, identification of the true nature of the PSAC protein
and/or components as well as expression or reconstitution in
a heterologous or artificial system would be highly appreciated
for in-depth structure-function analyses, inhibitor screening and
development.
Host Ion Channels
Besides the parasite-derived PSAC, host encoded transport
proteins of the erythrocyte may be exploited as drug targets if
their functionality changes with infection. Oxidative stress was
shown to alter potassium and chloride conductance of infected
red blood cells (Staines et al., 2001; Huber et al., 2004). However,
specific inhibitors are yet to be found to determine their potential
as anti-parasite drugs.
There is evidence that in the liver-stage, Plasmodium berghei
infection leads to a sevenfold increase in chloride conductance
of the host’s volume-regulated anion channel, VRAC, as
found using a human hepatoma cell line (Figure 1; Prudêncio
et al., 2009). Conductivity was inhibited by tamoxifen, and
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FIGURE 1 | Channels and transporters of parasites as targets for indirect, peripheral, and internal therapeutic attacks. HPM, host plasma membrane; HVM, host
vacuolar membrane; PPM, parasite plasma membrane; POMs, parasite organelle membranes; Mito, mitochondrion; Vac, vacuole. Abbreviations of the channel and
transporter proteins are explained in the text.
mefloquine at single-digit micromolar concentrations (Table 1).
The underlying mechanism of channel activation by the
parasite, the effect of estrogen receptor modulators on VRAC
conductivity, and, ultimately, whether indirect targeting of
VRAC would be suitable for malarial therapy of the liver stage
is not clear at this time. With the system and compounds at hand
further investigations will be possible that may shed some light
on the phenomenon.
Host V-Type Proton ATPase
In the search of new drug targets against L. donovani, Muylder
et al. chose a strategy of host-directed therapy. The amastigote
form of the parasite develops primarily inside phagocytic cells
and is inert to digesting enzymes. A screening assay using a
human macrophage cell line infected with L. donovani yielded
one hit compound, a µ-opioid receptor antagonist naloxonazine
(deMuylder et al., 2011;Table 1). It turned out that naloxonazine
upregulates expression of the V-type proton ATPase subunit C,
ATP6V0C. This upregulation was linked to an increase in the
volume of intracellular acidic vacuoles suggesting an indirect
effect on Leishmania amastigotes through host cell vacuolar
remodeling (de Muylder et al., 2016). How such a therapy would
be tolerated by the host and whether the parasites will find ways
to adapt to the remodeled vacuoles is not known.
Host Nutrient Channels and Transporters
We describe two examples illustrating that nutrient transport
of the host cell affects growth of P. berghei parasites, i.e., in
the blood-stage depending on the glycerol permeability of an
aquaporin (Liu et al., 2007), and in the liver-stage via arginine
transport (Meireles et al., 2017). Aquaporin-9 knockout mice
lack a functional glycerol channel in their erythrocytes. In this
environment, P. berghei, grew considerably slower compared to
wildtype erythrocytes, and infected AQP9-null mice survived
longer. The authors attribute the effect to reduced glycerol
levels in the parasite impeding glyceroplipid biosynthesis for the
build-up of membranes during growth. Similarly, knockdown
of the arginine-transporting SLC7A2 of the solute carrier family
decreased intra-hepatic growth and multiplication of P. berghei
parasites in vivo and ex vivo (Meireles et al., 2017). A sufficient
supply of arginine is required for the vital polyamine synthesis of
the parasites. Today, glycerol or arginine transport-modulating
small molecules have not been found and/or tested.
Together, although an indirect approach holds strong
potential against parasite infections, several gaps in basic
knowledge need to be filled with regard to the identity of
the involved transport proteins, selectivity of inhibitors, and
susceptibility/adaptability of the parasites.
Peripheral Targeting—Channels and
Transporters of the Parasite Plasma
Membrane
The substrate spectrum of the parasite-induced new permeation
pathways at the host cell membrane is broad. Transport proteins
at the parasite’s plasma membrane (Figure 1), in turn, appear
much more specific. These membrane proteins facilitate the
uptake of the main energy source, glucose, and precursors for
biosynthesis, such as nucleosides for DNA/RNA, or glycerol
for glycerolipids. Equally vital is the efficient release of waste
molecules derived from energy metabolism, e.g., lactic acid, or
from protein degradation, i.e., ammonia and urea. Nutrient
and metabolite transport often depends on transmembrane ion
gradients, e.g., of protons or sodium, generated by ATPases
and is further modulated by ion channels. Efficiency data on
compounds for peripheral parastite targeting are displayed in
Table 2.
Targeting Peripheral Nutrient and Metabolite
Transporters
Considering their significance for survival, it seems quite
surprising that plasmodia rely on a single hexose transporter, HT,
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TABLE 1 | Efficiency of compounds for indirect targeting.
Target Parasite
species
Compound name Effect on
protein
Effect on
parasite
Cell stage
in vitro
Effect
in vivo
Host
species
Reference
PSAC
P. falciparum
H3C
O
O
HN
N
N
N
NS
CH3
PRT1-20
– IC50
5µM
Trophozoites – Human Pain et al., 2016
 
CH3
N
NH3C
N
OO
NH
N
N
O
H3C
CH3
ISPA-28
– IC50
0.06µM
Trophozoites – Human Nguitragool et al.,
2011
VRAC (host) P. berghei
H3C O
N
CH3
CH3
Tamoxifen
IC50
4 µM
– Liver-stage – Human Prudêncio et al.,
2009
N
FF
F
F
F
F
HO
HN
H
Mefloquine
IC50
2 µM
– Liver-stage – Human Prudêncio et al.,
2009
ATP6V0C
(host)
L. donovani
O
HO
N
N
O
OH
N
OHH3C
CH3
HO
N
CH2
H2C
Naloxonazine
– IC50
3.5µM
Amastigotes
(Intracellular)
– Human de Muylder et al.,
2011
and a single lactic acid transporter, the latter being a member
of the microbial formate-nitrite-transporter family, FNT. Both
transporters are present at the plasma membrane and both have
been validated as novel antimalarial drug targets using cultured
parasites.
Glucose transporters
Soon after the identification of HT, first weak glucose-
analog inhibitors were described (Krishna and Woodrow,
1999; Woodrow et al., 1999; Joet et al., 2003). One of these
compounds, C3361 (Table 2), yielded Ki-values in the µM
range on glucose transport of Plasmodium berghei, Plasmodium
falciparum, Plasmodium yoelii, Plasmodium vivax, Plasmodium
knowlesi, Babesia bovis, and T. gondii (Joet et al., 2003; Blume
et al., 2011). C3361 was not only active in the blood-stage
but also inhibited parasite development in the liver-stage
of P. berghei with an IC50 of 11µM (Slavic et al., 2011).
The vector stages, however, were much less susceptible, and
a transmission block required 1mM. Interestingly, C3361
failed to inhibit growth of the related apicomplexan Babesia
parasites suggesting an alternative glucose transport pathway.
In fact, the B. bovis genome contains two putative hexose
transporter genes, of which only one has been characterized
so-far (Derbyshire et al., 2008). Knockout of the homologous
Toxoplasma glucose transporter, GT, led to moderate growth
inhibition. Apparently, it is dispensable for the survival of the
parasite. A search for alternative transporters in Toxoplasma
produced three more putative sugar transporters of which
one was found to be located at the plasma membrane.
Yet, a knockout failed to effect parasite growth. Contrary
to plasmodia, Toxoplasma seems not to rely exclusively on
glucose as an energy source. It is discussed that glutamine can
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TABLE 2 | Efficiency of compounds for peripheral targeting.
Target Parasite
species
Compound name Effect on
protein
Effect on
parasite
Cell stage
in vitro
Effect
in vivo
Host
species
Reference
HT Plasmodium
spp.
O
NH
NS
O
O
N
CH3
O
CH3
O CH3
CH3
TCMDC-125163
IC50
39 nM
IC50
1.24µM
Trophozoites – – Ortiz et al., 2015
O
OH
OH
OH
O
CH2HO
C3361
Ki
8.6–53µM
IC50
15–16µM
Trophozoites – – Joet et al., 2003;
Blume et al., 2011
– IC50
11 µM
Liver-stage – Human Slavic et al., 2011
HT1 B. bovis Ki
4.1µM
No inhibition
at 100µM
Trophozoites – – de Muylder et al.,
2011
GT1 T. gondii Ki
82µM
No inhibition
at 200µM
Tachyzoites – – Blume et al., 2011
FNT P. falciparum
CH3
O
O
O
OH
F
F
F
FF
CH3
O
O
HO
OH
F
F
F
FF
MMV007839
IC50
0.02–
0.17µM
IC50
0.14µM
Trophozoites – – Golldack et al.,
2017;
Hapuarachchi
et al., 2017
O
O
OH
F
F
F
FF
MMV000972
IC50
0.05–
0.17µM
IC50
1.70µM
Trophozoites – –
PT0 T. brucei
HO
O
N
N
UK5099
Inhibition at
250µM
– – – – Sanchez, 2013
PAT12 T.cruzi
CH3
H3C
H3C
CH3
OHO
CH3
CH3
Isotretinoin
– IC50
0.13µM
Epimastigotes – – Reigada et al.,
2017
IC50
30.6µM
Trypomastigotes – –
ENT1 Plasmodium
spp.
N
S
NH
H2C
O
H
N
O
O
ChemBridge 9001893
O
CH3
OO
O
O
CH3
H3C
H3C
ChemBridge 6946484
IC50
2.5–30 nM
IC50
3–55µM
Trophozoites – – Frame et al.,
2015b
(Continued)
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TABLE 2 | Continued
Target Parasite
species
Compound name Effect on
protein
Effect on
parasite
Cell stage
in vitro
Effect
in vivo
Host
species
Reference
ATP4 P. falciparum
HN
HN
NH
H3C
O
Cl
Cl
F
Cipargamin
– IC50
0.5–1.4 nM
Trophozoites Clearance
with 3-day
dosing, 30mg
per day
Human Rottmann et al.,
2010; Spillman
and Kirk, 2015
F
NHO
N
O
N
N
F F
F
SJ733
– IC50
30µM
Trophozoites – – Spillman and Kirk,
2015
Calcium
channels
Leishmania spp.
Trypanosoma
spp.
H3C NH
CH3
NO2
O
O
H3C
O
CH3
O
1,4-dihydropyridines
(e.g., Nifedipine)
−
−
IC50
2.6–181µM
Promastigotes/
Amastigotes
Trypomastigotes
−
−
−
−
Tempone et al.,
2009
Reimão et al.,
2010, 2011
A. castellanii
CH3
O
O
N
H
Cl
O
O
H3C
H3C
O
NH2
Amlodipine
– Large
inhibition at
1.2µM
Trophozoites – – Baig et al., 2013
L. infantum
CH3
N
H
Non-dihydropyridines (e.g., fendiline)
– IC50
2–16µM
Promastigotes – – Reimão et al.,
2016
T. cruzi – Epimastigotes – – Reimão et al.,
2016
K1/K2 T. brucei
CH3
CH3
F
F
O
HO
CH3
OH
S
F
Fluticasone
IC50
0.7µM
– – – – Schmidt et al.,
2017
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be used as a potent alternative energy source (Blume et al.,
2009).
More recent screenings for inhibitors of the plasmodial HT
using the Tres Cantos antimalarial compound set (TCAMS) and
the malaria box led to the discovery of nanomolar inhibitors,
e.g., TCMDC-125163 (Table 2) has an IC50 of 39 nM for
heterologously expressed HT, 3.2µM for the human red blood
cell glucose transporter GLUT1, and an EC50 of 1.24µM for
growth of cultured P. falciparum parasites. Binding of the
identified compounds occurred mostly non-competitive with
glucose and, hence, likely to a site different from the glucose
binding pocket (Ortiz et al., 2015).
Lactate and pyruvate transporters
The end products of glucose-based energy metabolism are
lactic acid in plasmodia, and pyruvic acid in trypanosomes. In
order to prevent detrimental acidification of the cytosol and
inhibition of the metabolic pathway by accumulating product,
such molecules need to be swiftly released from the cells. Lactate
transport in living P. falciparum parasites was experimentally
shown in the early 1990s (Kanaani and Ginsburg, 1991). It
took until 2015 that the responsible transporter was identified
by our and Kiaran Kirk’s group (Marchetti et al., 2015; Wu
et al., 2015). The protein is structurally and in terms of
transport mechanism unrelated to human lactate transporters
from the monocarboxylate transporter family (MCT). Instead,
the plasmodial lactic acid transporter is a member of the
microbial formate-nitrite transporter family, FNT. Besides L-
lactate, it transports D-lactate, as well as formate, acetate and
pyruvate by a proton cotransport mechanism (Wiechert and
Beitz, 2017; Wiechert et al., 2017).
Screening of the malaria box yielded two compounds,
MMV007839 and MMV000972 (Table 2), that efficiently block
PfFNT at nanomolar concentrations (Spangenberg et al., 2013;
Golldack et al., 2017). In vitro selection of a resistant P.
falciparum strain helped to locate the binding site at the
intracellular face of the transporter. The compounds, thus, need
to enter the parasite where they assume a lactate substrate-
like form carrying a negative charge for efficient binding.
Transport across consecutive membranes that shield the parasite
is achieved by a cyclic hemiketal form that is neutral and
lipophilic, see Table 2 (Golldack et al., 2017). FNTs are absent in
humans, however, some other protozoan parasites carry single
or multiple copies of FNT genes, e.g., Babesia spp., T. gondii,
and E. histolytica, representing putative targets. Kinetoplastids,
in turn, do not encode FNTs in their genomes, raising the
question of how monocarboxylate transport is achieved in these
organisms. In T. brucei, a high-affinity pyruvate transporter,
TbPT0, was recently discovered that is more related to polytopic
proteins from plants than to mammalian MCTs (Sanchez, 2013).
This transporter at the plasma membrane plus two additional
mitochondrial pyruvate transporters of T. brucei were found to
be inhibitable by the pyruvate-reminiscent compound UK5099
(Štáfková et al., 2016; Table 2).
Nucleobase and nucleoside transporters
Apart from nutrients and metabolites of energy metabolism,
precursors, and components of biosynthetic pathways are typical
substrates of parasite transporters. In this sense, a group of
transporters found at the plasma membrane of plasmodia
imports nucleobases and nucleosides. Four P. falciparum genes
encode equilibrative nucleoside transporters, ENT1–4 of which
ENT1 seems to provide the major uptake route (Downie et al.,
2006, 2008, 2010; Frame et al., 2012, 2015a). Small molecule
inhibitors were found by high throughput screening, e.g.,
ChemBridge no. 9001893 and 8946464 (Table 2), that inhibited
the P. falciparum PfENT1 with IC50 values in the low nanomolar
range. Efficiency was similar with the P. vivax and P. berghei
ENT1 proteins (Arora et al., 2016; Deniskin et al., 2016). The
compounds were less potent, however, in parasite cultures with
EC50-values from 0.8 to 6.5µM (Frame et al., 2015b).
Aquaporin solute channels
Plasmodium and Toxoplasma parasites express a single
aquaglyceroporin channel, AQP, at the plasma membrane
(Hansen et al., 2002; Pavlovic-Djuranovic et al., 2006). These
AQPs conduct water and small, uncharged solutes that
are relevant in glycerolipid biosynthesis (glycerol), protein
degradation (urea, ammonia), and oxidative stress (hydrogen
peroxide) (Hansen et al., 2002; Beitz et al., 2004; Zeuthen
et al., 2006; Wu et al., 2010; Wree et al., 2011; Almasalmeh
et al., 2014). Small, drug-like inhibitors for apicomplexan
AQPs are missing (Song et al., 2012), but their potential as
drug targets is underscored by a P. berghei PbAQP knockout
strain that exhibited strongly reduced growth, virulence, and
progression through the liver stage (Promeneur et al., 2007,
2018). T. brucei expresses three AQPs of which TbAQP2 is
a key factor for the uptake of the anti-trypanosomal drug
pentamidine (Uzcategui et al., 2004; Song et al., 2016).
The L. major AQP facilitates uptake of antimonite into the
parasite released from the anti-leishmanial drug stibogluconate
(Mukhopadhyay and Beitz, 2010; Mukhopadhyay et al.,
2011).
Drug repurposing/polyamine transporters
An attempt to repurpose already used drugs revealed that
retinoids, an established class for the pharmacotherapy of
severe acne, target parasitic nutrient transporters. Initially,
retinoic acid and retinol acetate were shown to inhibit the
growth of L. donovani (Mukhopadhyay and Madhubala, 1994).
More specifically, isotretinoin (Table 2) was found to block
a polyamine transporter, PAT12, when adding to cultures
of T. cruzi epimastigotes. In vitro growth of emerging
trypomastigotes and epimastigotes was inhibited with IC50 values
of 0.13 and 30.6µM, respectively. PAT12 is a member of
the polyamine and amino acid transporter family, AAAP, for
which isotretinoin displayed activity as a multi-target inhibitor
(Reigada et al., 2017). This shows that repurposing is a valid
tool and can promote research in the field of neglected
diseases.
Targeting Peripheral Ion Transporters and Channels
The establishment and maintenance of ion gradients across the
parasite plasma membrane is vital for the membrane potential,
osmotic balance, as well as for driving transport processes.
P-type ATPases are single protein units that convert energy
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from ATP hydrolysis into cation transport (Weiner and Kooij,
2016). ATP4 of P. falciparum was recently shown to act as
a sodium pump at the plasma membrane (Dyer et al., 1996;
Spillman et al., 2013). There is evidence that sodium export
by ATP4 is coupled to proton import. Whether cell death
upon blockade of ATP4 occurs due to cytosol acidification,
osmotic swelling, collapse of the electrochemical potential, or
a combination thereof is unknown (Spillman et al., 2013;
Spillman and Kirk, 2015). For whatever reason, blocking of
ATP4 is lethal for malaria parasites rendering ATP4 a most
attractive novel drug target. Analysis of the 400 malaria box
compounds yielded the surprisingly high number of 28 hits,
which further underscores the central role of ATP4 for parasite
viability.
ATP4/P-type sodium ATPase
Two previously identified ATP4 inhibitors already entered the
clinical trial stage. The clinical candidate cipargamin with a
spiroindolone scaffold (Table 2) is thought to bind to the
transport path of ATP4 from the intracellular entry site as
deduced from in vitro selection of resistance mutations (Spillman
and Kirk, 2015). Growth of sensitive P. falciparum strains
was inhibited with IC50-values in the range of 0.5–1.4 nM.
Application of a single 100mg kg−1 dose in an in vivo mouse
model study killed all P. berghei parasites. In human trials,
a 3-day dosing regime with 30mg per day led to parasite
clearance (Rottmann et al., 2010; White et al., 2014). Cipargamin
exhibited low toxicity in humans, high oral bioavailability and
suitable half-life. Other related ATP4-inhibiting spiroindolones
have been found to be similarly potent (Spillman et al., 2013).
The second promising candidate undergoing a clinical trial is the
dihydroisoquinolone SJ733 (Jiménez-Díaz et al., 2014; Table 2).
It shows more distant structure similarities to cipargamin with
the 5-membered heterocycle of the indolone moiety replaced by
a 6-membered ring (Jiménez-Díaz et al., 2014; Spillman and Kirk,
2015; Crawford et al., 2017). Although resistance mutations were
selectable in vitro by sub-lethal concentrations, ATP4 inhibitors,
when dosed properly, might prove advantageous against the
rise of resistant strains in the clinic due to their fast acting
property.
Drug repurposing/calcium channels
Drug repurposing approaches aim at ion channels at the
plasma membrane of kinetoplastids. Several established 1,4-
dihydropyridine calcium channel blockers used for the treatment
of hypertension in humans were tested on various Leishmania
and Trypanosoma species. Nifedipine, amlodipine, bepridil,
nimodipine, and others showed weak effects in vitro with IC50-
values in the micromolar range (Maya et al., 2000; Tempone
et al., 2009; Reimão et al., 2010, 2011). Amlodipine and lacidipine
administered in four weekly single doses of 10mg kg−1 reduced
the parasite burden of L. donovani-infected BALB/c mice by
75–85% (Palit and Ali, 2008). Amlodipine was also tested for
activity against cultured amoebae of Acanthamoeba castellanii
and largely inhibited growth at 1.2µM (Baig et al., 2013).
The non-dihydropyridine calcium channel blockers fendiline,
mibrefadil, and lidoflazine inhibited in vitro growth of L.
infantum promastigotes and T. cruzi epimastigotes with IC50-
values from 2–16µM (Reimão et al., 2016). Verapamil, however,
failed to inhibit growth of L. donovani promastigotes, but seemed
to reverse the resistance against stibogluconate by an unknown
mechanism (Neal et al., 1989; Valiathan et al., 2006). Although
being calcium channel blockers in humans, the target in the tested
parasites remains to be established.
Drug repurposing/potassium channels
Recently, a screening by the National Center for Advancing
Translational Sciences Small Molecule Resource identified
fluticasone, an established corticosteroid for the treatment of
asthma, to inhibit the T. brucei potassium channels TbK1 and
TbK2. The proteins were localized to the parasite’s plasma
membrane and electrophysiologically characterized in Xenopus
oocytes (Steinmann et al., 2015). Fluticasone was found to
inhibit the TbK1/TbK2-mediated currents at an IC50 of 0.7µM
(Schmidt et al., 2017).
Internal Targeting—Channels and
Transporters of Parasite Organelle
Membranes
Drugs that need to enter the parasite’s cytosol encounter several
more challenges than compounds acting from the outside.
Diffusional uptake across the plasma membrane requires high
lipophilicity, small molecule size, and absence of charged
moieties. Alternatively, compounds can be shuttled into the cell
by a more active type of transport via endogenous channels
and transporters. This route is taken for instance by antimonite
released from stibogluconate in Leishmania therapy or by
pentamidine against trypanosomes. In both cases, resistance
mutations of a transporting aquaglyceroporin efficiently prevent
the drugs from entering the parasites. Another factor is the
metabolic stability of the drug within the parasite cell. This area
is not well studied, yet it is conceivable that inactivation by
chemical modification may well occur in a similar fashion as
in the host cells, which detoxify xenobiotics e.g., by oxidation
and conjugation reactions. Finally, drugs that actually made
it to the site of action in a functional form may be pumped
out of the parasite cell by drug resistance transporters. The
prominent example is the chloroquine resistance transporter,
CRT. Table 3 gives an overview on the new developments
of compound targeting channels and transporters of internal
organelle membranes.
Despite these challenges, all currently used drugs in anti-
parasite therapy act at internal sites. It remains to be seen how
a shift to peripheral or even indirect attacks will affect resistance
formation.
Artemisinins/Sarcoplasmic P-type Calcium ATPase
SERCA/ATP6
Artemisinin (Table 3) and derivatives are the most important
antimalarials today. The molecules contain a peroxo moiety. It is
discussed that ironII from heme when released from hemoglobin
during degradation in the digestive vacuole chemically activates
the artemisinins producing reactive oxygen species that damage
proteins more or less specifically inside the mitochondria
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(Asawamahasakda et al., 1994; Moore et al., 2011) or at other sites
in the cell including DNA as a target. Evidence further points to
a P-type calcium ATPase, SERCA, or ATP6, at the sarcoplasmic
endoplasmic reticulum as one of the affected proteins (Eckstein-
Ludwig et al., 2003; Naik et al., 2011; Abiodun et al., 2013;
Pulcini et al., 2013; Krishna et al., 2014; Nunes et al., 2016).
However, there is a mismatch of artemisinin efficiency on the
parasites and on heterologously expressed ATP6. In P. falciparum
cultures, IC50-values were 11 and 13 nM tested on a chloroquine
resistant (K1) and a sensitive (NF54) strain, respectively (del
Pilar Crespo et al., 2008). The artemisinins also showed some
potency on several other protozoan parasites, i.e., T. gondii
(Berens et al., 1998; Jones-Brando et al., 2006; Hencken et al.,
2010), T. brucei, T. cruzi, L. donovani, L. major (Yang and Liew,
1993; Mishina et al., 2007), and Babesia gibsoni (Iguchi et al.,
2015) yielding EC50-values from 0.36 to 120µM. For Leishmania
spp., artemisinin exhibited in vivo activity in infected hamster
and BALB/c mice models (Ma et al., 2004; Sen et al., 2010;
Ghaffarifar et al., 2015). Naegleria fowleri, a problematic, cyst-
forming amoeba, has been shown to be sensitive to artemisinin
in vitro (Cooke et al., 1987), whereas treatment failed in a mouse
model (Gupta et al., 1995). Purified recombinant P. falciparum
ATP6, however, could not be directly inhibited by artemisinin
or derivatives (Cardi et al., 2010; Arnou et al., 2011), and full
inhibition of yeast expressed SERCA of T. gondii required high
concentrations of 10µM (Nagamune et al., 2007). The small
molecule arterolane (Table 3) has a different scaffold than the
artemisinins but equally contains a peroxo group and, thus,
should be capable of releasing reactive oxygen species. When
tested on P. falciparumATP6 expressed in Xenopus oocytes it was
found to be clearly less potent than artemisinin with a Ki-value
of 7.7µM; yet, parasite growth was inhibited a very low IC50
of 1.5 nM similar to artemisinin. These mixed results show that
ATP6/SERCA is probably not the main target of the artemisinins.
Still, parasite SERCA/ATP6 seems to hold potential as
a therapeutic target, because thapsigargin (Table 3), a plant
sesquiterpene lactone and general SERCA inhibitor, killed
cultured chloroquine resistant and sensitive P. falciparum
parasites with IC50 of 246 and 298 nM (del Pilar Crespo et al.,
2008; Abiodun et al., 2013). Thapsigargin further inhibited
growth of T. gondii, Trypanosoma spp., L. donovani, E.
invadens, and Neospora canium with EC50-values in the range
of 0.5–39µM (Kim et al., 2002; Mishina et al., 2007; Martínez-
Higuera et al., 2015). Yeast expressed T. gondii SERCA was fully
inhibited by thapsigargin at 1µM (Nagamune et al., 2007).
Atovaquone/Mitochondrial Cytochrome bc1 Complex
A key function of mitochondria in general is the build-up of a
steep proton gradient across the inner mitochondrial membrane,
which is used to drive ATP synthesis by the F-type ATPase,
or ATP synthase. To this end, the inner membrane harbors
a cytochrome bc1 complex. The bc1 proteins use ubiquinone,
also called coenzyme Q, as a redox cofactor in electron transfer
reactions (Q-cycle), which free four protons that are transported
to the intermembrane space in the process (Crofts et al., 1999a,b;
Crofts, 2004).
The drug atovaquone (Table 3), a ubiquinone analog and
cytochrome bc1 complex inhibitor, is in use against malaria,
toxoplasmosis and babesiosis for many years. It interferes
with ubiquinone cofactor binding to the Q0 site as shown by
manifesting resistance mutations in this region of the protein
(Fry and Pudney, 1992; Srivastava et al., 1999; McFadden et al.,
2000; Kessl et al., 2007; Vallières et al., 2012; Siregar et al.,
2015). Combination of atovaquone with proguanil lowers the
IC50 from 2 nM to 400 pM probably by a synergistic mechanism
as proguanil destroys the mitochondrial membrane potential
in the presence of an electron transport inhibitor (Srivastava
and Vaidya, 1999). Several resistant strains have formed during
the use of atovaquone (Hutchinson et al., 1996; Painter et al.,
2007; da Cruz et al., 2012). Since the cytochrome bc1 complex
is common to mitochondria of all species is was possible to
inhibit the growth of other parasites as well. Potency against
T. gondii was sub-micromolar in vitro, i.e., tachyzoites in human
foreskin fibroplasts, and in vivo using a mouse model with IC50-
values of 0.14 and 0.85µM, respectively (Doggett et al., 2012).
Similarly, atovaquone acted on Babesia spp. in vitro and in vivo
in hamsters (Hughes and Oz, 1995; Wittner et al., 1996; Matsuu
et al., 2008). In dog and human studies, combination with the
antibiotic azithromycin turned out to be positive (Krause et al.,
2000; Birkenheuer et al., 2004; Di Cicco et al., 2012; Checa et al.,
2017). Treatment of L. donovani infections in a mouse model
were less successful resulting only in a 30% lower parasite burden
(Croft et al., 1992).
A related hydroxynaphthoquinone compound, buparvaquone
(Table 3), is used for the treatment of theileriosis in cattle
(McHardy et al., 1985; Minami et al., 1985; Muraguri et al.,
1999; Mhadhbi et al., 2010), and horses (Zaugg and Lane, 1989).
Anti-leishmanial activity was evaluated in vitro for L. donovani,
Leishmania aethiopica, L. major, Leishmania amazonensis,
Leishmania mexicana, Leishmania panamensis, L. infantum,
Leishmania chagasi, L. braziliensis, and L. tropica promastigotes
and amastigotes resulting in IC50-values of 0.001–5.495µM
(Mäntylä et al., 2004a,b; Reimão et al., 2012; Jamal et al., 2015).
Animal models showed that the in vivo efficiency was higher
when prodrugs of buparvaquone were applied (Croft et al., 1992;
Garnier et al., 2007) or when a nanoliposomal drug preparation
was used (da Costa-Silva et al., 2017).
In the search for alternative chemical scaffolds, decoquinate
(Table 3), a 4-oxo-quinoline, was tested. However, the overall
structure is still similar to ubiquinone. The compound is in use
in veterinary medicine against coccidia (Miner and Jensen, 1976;
Ricketts and Pfefferkorn, 1993). When tested against blood-stage
as well as liver-stage P. falciparum, in either case nanomolar IC50
values were found at low host cell toxicity (da Cruz et al., 2012).
Another potent inhibitor of the cytochrome bc1 complex with
good selectivity for P. falciparum is the dihydroacridinedione
WR249685 (Table 3), which has an IC50 of 3 nM on the in
vitro growth of the parasites (Biagini et al., 2008). Screening
of the TCAMS library for cytochrome bc1 complex inhibition
yielded one efficient compound, TCMDC-135546 (Table 3), with
an IC50 of 22 nM on parasite growth (Raphemot et al., 2015).
Naphthoquinone esters were derived from the anticancer drug
rhinacanthin and showed low nanomolar IC50-values on the
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growth of P. falciparum. Notably, the molecules seem to bind
to the Qi ubiquinone site of cytochrome bc1 rather than Q0 as
the above-mentioned compounds (Kongkathip et al., 2010). In a
diversity oriented synthesis approach, macrolactame derivatives
were generated that yielded nanomolar EC50-values and are
thought to target the Qi site as well (Comer et al., 2014;
Lukens et al., 2015). Finally, more compounds were derived from
endochin, an experimental antimalarial of the 1940s, with the aim
to improve solubility and metabolic stability in the host. Such
compounds were found not to inhibit the human cytochrome bc1
complex but to very efficiently target theQi site of the cytochrome
bc1 complex of falciparum and vivax plasmodia from various
clinical field isolates as well as T. gondii and Babesia microti
(Doggett et al., 2012; Nilsen et al., 2013; Lawres et al., 2016).
Leishmania spp., however, were much less susceptible to this type
of inhibitors with IC50-values in the micromolar range (Ortiz
et al., 2016).
Diamidines/Mitochondrial ATP Synthase
Similar to the artemisinins in plasmodia, the mode of diamidine
action, e.g., pentamidine, in trypanosomes is not fully resolved.
Screening of an diamidine library yielded furamidine (Table 3)
and related compounds that act comparably to pentamidine
against T. brucei parasites in mice and rhesus monkeys
(Rane et al., 1976; Steck et al., 1982). Further, a prodrug of
furamidine, DB289 (Table 3), with better oral availability was
developed (Ismail et al., 2003; Ansede et al., 2004). Regarding
transporter targeting, it was found that the F1F0-ATPase, i.e.,
the mitochondrial proton gradient-driven ATP synthase, was
inhibited at concentrations around 10µM and caused a collapse
of the mitochondrial membrane potential. The efficiency of
diamidines on the growth of trypanosomes, however, is clearly
lower, i.e., in the submicromolar range, indicating that ATP
synthase is not the main target. It was also suggested that the
compounds inhibit other ATPases (Lanteri et al., 2008). DB289
entered phase III clinical trials as the first orally available drug
against blood stage human African trypanosomiasis. However,
due to manifestation of delayed renal insufficiency in a number
of recipients, further development was terminated (Harrill et al.,
2012). Two related aza analogs of furamidine (DB820, CPD0801)
are still followed up on as they have shown efficiency against
T. brucei in a mouse model of second stage trypanosomiasis
(Wenzler et al., 2009; Ward et al., 2011).
G25/Mitochondrial Choline Transport
The notion that a choline-related compound, named G25
(Table 3) carrying two quaternary ammonium moieties spaced
by a 16-carbon linker, efficiently kills malaria parasites led to
the idea that choline transport might be a valid antimalarial
target (Wengelnik et al., 2002; Biagini et al., 2004). Besides
P. falciparum, also T. brucei and L. mexicana turned out to
be sensitive to G25 (Ibrahim et al., 2011). The mode of action
remains unclear. Besides the notion that these compounds
inhibit choline transport, it was reported that the mitochondrial
structure and function of trypanosomes was affected (Ibrahim
et al., 2011; Macêdo et al., 2013). An RNA interference approach
in the blood stream form of T. brucei hinted at the involvement of
a member of a mitochondrial carrier protein family, TbMCP14,
which is unrelated to mammalian carriers (Schumann Burkard
et al., 2011; de Macêdo et al., 2015).
Aminomethylenediphosphonate/Vacuolar-Type
Inorganic Pyrophosphatase
Vacuolar-type pyrophosphatases, V-PPases, seem to be absent
in vertebrates, yet have vital functions in protozoan energy
conservation and membrane transport. Accordingly, they
may represent suitable drug targets (Rodrigues et al., 2000;
Drozdowicz et al., 2003). Yeast-expressedV-PPase fromT. gondii,
TgVP1, was inhibitable by aminomethylenediphosphonate,
AMDP (Table 3), with an IC50 of 0.9µM. The presence of V-
PPases has also been shown in P. falciparum and T. cruzi (Urbina
et al., 1999; McIntosh et al., 2001). Anti-parasitic, drug-like
molecules targeting V-PPases are yet to be found.
Targeting Drug Efflux Transporters
Drug resistance due to expedited export of the compounds is a
key factor in pharmacotherapy not only of anti-infectives but in
general. The loss of drug action may be reversed by inhibition of
the responsible efflux transporter.
Verapamil, (Dimeric) Quinine, Saquinavir/Digestive
Vacuole Chloroquine Resistance Transporter
The discovery of chloroquine was a breakthrough in malaria
therapy. It acts by inhibiting heme detoxification in the form
of polymerized hemozoin in the digestive vacuole (Foley
and Tilley, 1997). Promoted by monotherapeutic use and
widespread underdosing in eradication programs, however,
resistant P. falciparum strains were selected over the years
rendering chloroquine largely useless today (Wellems et al.,
1991; Waller et al., 2003). Resistance mutations were found
in one particular gene of unknown function at that time. It
turned out that the mutations resulted in a gain-of-function
transporter shuttling chloroquine out of the digestive vacuole
at a strongly increased rate (Fidock et al., 2000; Lakshmanan
et al., 2005). The physiological role of the chloroquine-resistance-
transporter, CRT, is still elusive. However, a variety of amino
acids, polyamines and peptides have been found to be CRT
substrates (Juge et al., 2015). Several attempts have been
undertaken to block CRT with the aim to reverse chloroquine
resistance. The calcium channel blocker verapamil (Table 3) was
shown to inhibit CRT expressed in Xenopus oocytes with an IC50
of 30µM (Ye and van Dyke, 1988, 1994; Tanabe et al., 1989).
In the same system, quinine, a natural product and chloroquine
analog, yielded an IC50 of 48µM (Martin et al., 2009), and the
antiretroviral drug saquinavir was effective at 13µM (Martin
et al., 2012). Chemical synthesis of dimeric quinines lowered the
IC50 to 1µMon CRT-expressing oocytes and efficiently inhibited
parasite growth in the nanomolar range (Hrycyna et al., 2014).
The resistance reversing effect of verapamil cannot be
exploited in humans, because the required dose would be too
high to be tolerable (Ye and van Dyke, 1988). One approach
was to develop a drug-like compound with dual functionality,
i.e., blockade of hemozoin formation plus inhibition of CRT
(Burgess et al., 2006; Kelly et al., 2009). The obtained dibemethin
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derivates (Table 3) showed IC50 values of 26 nM on parasite
growth, yet potency on the isolated CRT protein was only 69µM.
Bioavailability appeared sufficient after oral administration in
mice (Zishiri et al., 2011).
ACT-213615, ACT-451840/Digestive Vacuole
Multidrug Resistance Transporter 1
Based on similarity to human multidrug resistance transporters
in terms of sequence and function another transporter of the
digestive vacuole of malaria parasites was termed multidrug
resistance transporter 1, MDR1 (Foote et al., 1989; Cowman
et al., 1991). MDR1 transport is directed into the digestive
vacuole. This way, mefloquine, artemisinin, and artesunate are
thought to be trapped by compartmentalization preventing the
drugs from hitting their target in the sarcoplasmic endoplasmic
reticulum (Reed et al., 2000; Pickard et al., 2003; Price et al., 2004;
Rohrbach et al., 2006). Resistance was increased in strains with
multiple copies of the pfmdr1 gene (Cowman et al., 1994; Pickard
et al., 2003). For quinine in turn, it is required that MDR1 is
functional to deliver the compound to its site of action inside
the digestive vacuole. Therefore, a transport decreasing N1042D
mutation of MDR1 was made responsible for quinine resistance
(Rohrbach et al., 2006). Apart from transport of antimalarial
drugs, MDR1 appears to be vital for the malaria parasite, because
in cell viability screening and subsequent analyses, two small-
molecule compounds were found to target MDR1. ACT-213615
(Table 3) is proposed to inhibit either PfMDR1 directly or a
regulating protein upstream of it yielding an EC50 value of 4 nM
on parasite growth (Brunner et al., 2012, 2013). The second,
highly related compound, ACT-451840 (Table 3), was even more
potent and a single nucleotide polymorphism in the MDR1 gene
was identified that turned out to be responsible for resistance
against the compound. The compound was well tolerated in first
clinical trials, however, none of the eight tested subjects could be
completely freed from parasites (Krause et al., 2016; Le Bihan
et al., 2016; Ng et al., 2016). The physiological substrates and
function of MDR1 remain to be established.
CONCLUSION
The identification of anti-parasitic targets at the parasite’s plasma
membrane or even at host membranes opens up options
for peripheral or indirect therapeutic attacks (Figure 1). This
approach holds the potential to limit resistance formation
because the only remaining line of defense is mutational
modification of the drug binding site at the target protein. It is
thinkable that massive upregulation of target protein expression
may also reduce efficiency, yet at high energetic cost for the
parasite.
Still, most currently addressed targets are located inside the
parasite. Here, specificity must be taken into account. Drugs
affecting vital functions by hitting multiple targets, e.g., the
artemisinins by eliciting oxidative stress, are hard to defend
by the parasite at the various target sites. However, several
ways exist to interfere with drug action by acting directly
on the molecular entity. Drug uptake can be prevented if
transporters are required to deliver the compound to the cytosol,
e.g., pentamidine via TbAQP2. The drug can be chemically
modified or compartmentalized, e.g., artesunate transport into
the digestive vacuole by MDR1. Finally, the compound can
be shuttled out to keep the concentration below a harmful
level, e.g., chloroquine via CRT. Drug metabolism and transport
issues cannot be fully appreciated beforehand. Hence, in the
search for potent anti-infectives against parasites and bacteria
alike, phenotypic screenings have proven more successful than
specific approaches in designing inhibitors for a selected target
protein.
The ideal anti-parasitic drug compound should i. reach the site
of action independent of parasite transport proteins, ii. be specific
for the parasite but not necessarily for a single target protein,
iii. act fast, iv. be metabolically stable, and v. be safe for the
patient. Meeting such demands and circumventing the influence
by the parasite may be eased by addressing parasite-specific
proteins at the periphery.
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